Application of the murine anti-Gd-2 antibody 14.Gd-2a for diagnosis and therapy of neuroblastoma.
We have tested the sialoganglioside monoclonal antibody Gd-2a for scintigraphic diagnostic and for immunotherapy in children with neuroblastoma stage IV. We could confirm tumor sites with Gd-2a scans in 1/2 children. Doses of 20-60 mg/m2 were administered daily for 5-10 days. 2/2 children with multiple tumor sites showed significant tumor regression. Four children, treated preventively, are still in clinical remission. One child showed tumor progression despite Gd-2a treatment. Adverse effects included itching, rashes, and pain.
Reuland
P
P
Department of Nuclear Medicine, University of Tübingen, F.R.G.
Handgretinger
R
R
Smykowsky
H
H
Dopfer
R
R
Klingebiel
T
T
Miller
B M
BM
Reisfeld
R A
RA
Gallagher
S
S
Koscelniak
E
E
Treuner
J
J
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005732:Gangliosides / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008297:Male; D009447:Neuroblastoma / Q000000981:diagnostic imaging* / Q000276:immunology*; D011877:Radionuclide Imaging
D000911:Antibodies, Monoclonal; D005732:Gangliosides; D007457:Iodine Radioisotopes